Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT04378439 · HIV/AIDS, STI, and more
NCT06953479 · HEPATITIS C (HCV), Incarceration, and more
NCT07429864 · HBV, HBV Coinfection, and more
NCT05653232 · HCV
NCT05968573 · Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)
New Zealand
Auckland
New Zealand
Christchurch
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions